The direct oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban ( Xarelto , and generics) are frequently used for treatment of acute venous thromboembolism (VTE) and are usually continued for at…
Med Lett Drugs Ther. 2026 Jun 22; 68(1757):103 doi:10.58347/tml.2026.1757f
The direct oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban ( Xarelto , and generics) are frequently used for treatment of acute venous thromboembolism (VTE) and are usually continued for at least 3 months. The other DOACs (edoxaban [Savaysa] and dabigatran [ Pradaxa , and generics]) are alternatives for long-term treatment, but they require prior treatment with low-molecular-weight heparin for ≥5 days. Until recently, no large randomized trial directly comparing the safety of apixaban and rivaroxaban for treatment of VTE was available.
Balfaxar (Octapharma), a human plasma-derived four-factor prothrombin complex concentrate (PCC), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent…
Med Lett Drugs Ther. 2024 Feb 19; 66(1696):31-2 doi:10.58347/tml.2024.1696d
Balfaxar (Octapharma), a human plasma-derived four-factor prothrombin complex concentrate (PCC), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent surgical/invasive procedure. It is the second four-factor PCC to become available in the US; Kcentra , which has been available since 2013, is approved for the same indication and for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. Balfaxar is marketed in Canada and Europe as Octaplex .
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of…
Med Lett Drugs Ther. 2024 Jan 8; 66(1693):1-8 doi:10.58347/tml.2024.1693a
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for…
Med Lett Drugs Ther. 2022 Jul 25; 64(1655):113-20
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Med Lett Drugs Ther. 2021 Nov 1; 63(1636):175-6
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor…
Med Lett Drugs Ther. 2018 Jun 18; 60(1549):99-101
Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto) . Andexanet alfa is the second antidote for a direct oral anticoagulant to become available in the US, and the fi rst for factor Xa inhibitors. Idarucizumab (Praxbind) was approved in 2015 for reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa) . Andexanet alfa has not been approved to date for reversal of anticoagulation with the direct factor Xa inhibitors edoxaban (Savaysa) or betrixaban (Bevyxxa) .
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). Updated US guidelines…
Med Lett Drugs Ther. 2018 Mar 12; 60(1542):41-8
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). Updated US guidelines for treatment of VTE were published in 2016.
The FDA has approved betrixaban ( Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who…
Med Lett Drugs Ther. 2018 Jan 1; 60(1537):4-5
The FDA has approved betrixaban ( Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have moderately or severely restricted mobility and other risk factors for VTE. Betrixaban is the first oral anticoagulant to be approved in the US for this indication.
With the widespread adoption of the CHA 2 DS 2 -VASc scoring system, oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial fibrillation. Atrial fibrillation…
Med Lett Drugs Ther. 2017 Feb 27; 59(1515):35-6
With the widespread adoption of the CHA 2 DS 2 -VASc scoring system, oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial fibrillation. Atrial fibrillation has, however, been associated with an increased risk of falls, and older patients starting warfarin for atrial fibrillation have a high rate of hospitalization for intracranial bleeding. Many practitioners are reluctant, therefore, to prescribe an oral anticoagulant for elderly patients who are at high risk for falls.
Direct-to-consumer advertisements continue to urge patients who take warfarin ( Coumadin , and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral…
Med Lett Drugs Ther. 2016 Apr 11; 58(1492):45-6
Direct-to-consumer advertisements continue to urge patients who take warfarin ( Coumadin , and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral anticoagulants.
The FDA has approved edoxaban ( Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in…
Med Lett Drugs Ther. 2015 Mar 30; 57(1465):43-5
The FDA has approved edoxaban ( Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Med Lett Drugs Ther. 2014 Jul 7; 56(1446):53-8
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.